• 提示：詳情請下載說明書。

• 產(chǎn)品描述： OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity

• 靶點： KDR:9 nM (IC50);Flt-1:8 nM (IC50);Kit:80 nM (IC50);PDGFRβ:6900 nM (IC50);PDGFRα:3408 nM (IC50);CSF-1R:15 nM (IC50);c-Raf:41 nM (IC50);Flt-3:1303 nM (IC50);Lck:22 nM (IC50);Abl:4738 nM (IC50);Apoptosis;c-Fms;Raf;VEGFR;FLT;CSF-1R;Src;c-Kit

• 體內(nèi)研究：
  OSI-930 (oral gavage; once a day; 38 days; 200 mg/kg) exhibits potent antitumor activity in a broad range of preclinical xenograft models

• 參考文獻：
  1. Garton AJ, et al. OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res. 2006, 66(2):1015-1024. 2. Lin HL, et al. Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug. Drug Metab Dispos. 2011, 39(2), 345-350.

• 溶解性： DMSO  :  50  mg/mL  (112.75  mM;  Need  ultrasonic)

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	2.255 ml	11.275 ml	22.55 ml
  5 mM	0.451 ml	2.255 ml	4.51 ml
  10 mM	0.226 ml	1.128 ml	2.255 ml
  50 mM	0.045 ml	0.226 ml	0.451 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號：

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *